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Abstract
Low bone mineral density (BMD) and osteoporosis remain frequent problems in patients with inﬂammatory bowel diseases (IBDs).
Several guidelines with nonidentical recommendations exist and there is no general agreement regarding the optimal approach for
osteoporosis screening in IBD patients. Clinical practice of osteoporosis screening and treatment remains insufﬁciently investigated.
In the year 2014, a chart review of 877 patients included in the Swiss IBD Cohort study was performed to assess details of
osteoporosis diagnostics and treatment. BMD measurements, osteoporosis treatment, and IBD medication were recorded.
Our chart review revealed 253 dual-energy x-ray absorptiometry (DXA) scans in 877 IBD patients; osteoporosis was prevalent in
20% of tested patients. We identiﬁed widely differing osteoporosis screening rates among centers (11%–62%). A multivariate logistic
regression analysis identiﬁed predictive factors for screening including steroid usage, long disease duration, and perianal disease;
even after correction for all risk factors, the study center remained a strong independent predictor (odds ratio 2.3–21 compared to the
center with the lowest screening rate). Treatment rates for patients with osteoporosis were suboptimal (55% for calcium, 65% for
vitamin D) at the time of chart review. Similarly, a signiﬁcant fraction of patients with current steroid medication were not treated with
vitamin D or calcium (treatment rates 53% for calcium, 58% for vitamin D). For only 29% of patients with osteoporosis
bisphosphonate treatment was started. Treatment rates also differed among centers, generally following screening rates. In patients
with longitudinal DXA scans, calcium and vitamin D usage was signiﬁcantly associated with improvement of BMD over time.
Our analysis identiﬁed inconsistent usage of osteoporosis screening and underuse of osteoporosis treatment in IBD patients.
Increasing awareness of osteoporosis as a signiﬁcant clinical problem in IBD patients might improve patient care.
Abbreviations: ACG = American College of Gastroenterology, AGA = American Gastroenterological Association, BMD = bone
mineral density, CD = Crohn disease, CI = conﬁdence interval, DXA = dual-energy x-ray absorptiometry, IBD = inﬂammatory bowel
disease, PTH = parathyroid hormone, SIBDCS = Swiss IBD cohort study.
Keywords: bone mineral density, inﬂammatory bowel diseases, osteoporosis, prevention, screening
1. Introduction
Osteoporosis is a clinically relevant and frequent complication in
patients with inﬂammatory bowel disease (IBD).[1–3] Compared
to controls, the fracture risk for IBD patients is increased by
approximately 40% to 60%.[4,5] Risk factors for osteoporosis
and osteopenia in IBD patients include activity and severity of gut
inﬂammation, perianal disease including ﬁstulae, systemic steroid
usage, intestinal malabsorption leading to calcium and vitamin D
deﬁciency, low body mass index, and advanced age.[1,6–22]
Bone mineral density (BMD) remains a widely accepted
parameter to quantify osteopenia and osteoporosis. Dual-energy
x-ray absorptiometry (DXA) is normally used to assess BMD.
BMD can predict fracture risk[23,24] and a BMD of one standard
deviation below the age adjusted mean increases the relative
fracture risk by 1.6 to 2.6.[23]
Current guidelines recommend screening for osteoporosis in
high-risk individuals[22,25–33] (Table 1). For IBD patients recom-
mendations differ in published guidelines by the European Crohn
and Colitis Organization, the American College of Gastroenterol-
ogy (ACG), the AmericanGastroenterological Association (AGA),
and the British Society of Gastroenterology.[22,25–33] Although all
guidelines recommend a DXA scan in individuals with signiﬁcant
steroid use and/or recurrent or persistently active disease, each
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guidelinementions speciﬁc additional risk situations. Applicability
of these guidelines and compliance with osteoporosis screening for
IBD has been insufﬁciently studied.
Adequate treatment can reverse osteoporosis and prevent
osteoporotic fractures even in high-risk individuals including
postmenopausal women, older men with osteoporosis, or
glucocorticoid-treated patients.[34–36] There is general agreement
that high-risk individuals with decreased BMD should have
adequate dietary calcium intake (1000–1200mg per day),
otherwise calcium supplements should be prescribed. Similarly,
an intake of 800 to 1000 international units (IU) of vitamin D per
day is recommended.[35,37,38] Furthermore, individuals with
osteoporosis should receive osteoporosis medication in addition
to calcium and vitamin D treatment (eg, bisphosphonates,
parathyroid hormone [PTH] analogues, and estrogens).[35,37,38]
During systemic glucocorticoid therapy calcium and vitamin D
intake should be adequate, and depending on age, hormonal
state, and BMD, additionally bisphosphonates or PTH analogues
are recommended.[35,37–41] Several guidelines with similar
recommendations exist for the treatment of patients with
osteoporosis and IBD.[1,18,27,42] It remains unclear, how these
guidelines are applied in clinical practice.
To study screening and treatment of low BMD in IBD patients
we used data of the Swiss IBD cohort study (SIBDCS), a
prospective long-term study of well characterized IBD patients.
Our data indicate divergent screening and treatment rates for IBD
patients and possibilities to improve patient care.
2. Patients and methods
The SIBDCS is a prospective cohort study of IBD patients.
General information regarding the presence of osteopenia/
osteoporosis is recorded in the data base but the dates of various
DXA scans as well as T scores and Z scores are not. Therefore, a
manual review of patient charts was performed in the year 2014.
Our chart review covered 4 tertiary care hospitals (providing care
from specialists in a large hospital) and 2 secondary care centers.
For each available DXA scan T scores and Z scores for hip
and lumbar spine were retrieved. Any additional information
regarding osteoporosis and osteopenia in the patient chart was
also recorded and evaluated as speciﬁed below. In addition,
information regarding steroid usage ≥10mg/day, treatment with
biologicals (Inﬂiximab, Adalimumab, and Certolizumab pegol)
and osteoporosis treatment (calcium, vitamin D, and bisphos-
phonate medication) was noted. For all treatment parameters,
both current usage and any usage within patient history were
recorded. For the analysis of the association of steroid treatment
with osteoporosis, osteopenia, and normal BMD, treatment
information was retrieved from SIBDC data base.
DXA measurements were performed in the femur (femoral
neck and/or total hip) and/or lumbar spine. For the T score data
were compared to the BMD of a sex-matched young adult
reference population while for the Z scores data were compared
to an age-, sex-, and ethnicity-matched reference population.[35]
In postmenopausal women and in men ≥50 years, osteoporosis
and osteopenia were deﬁned by a T score 2.5 and <1,
respectively, in lumbar spine, total hip, or femoral neck.[35] For
premenopausal women and younger men, the diagnosis of
osteoporosis is not possible on BMD values alone but a Z score of
2 is a helpful parameter.[35,43]
A total of 877 patient charts from 6 centers were reviewed for
evidence of one or more past DXA scans.[22] Diagnosis or
exclusion of osteoporosis and osteopenia was done as described
in our previous study,[22] in brief: osteoporosis was deﬁned as T
scores 2.5 and Z scores 2, whereas osteopenia was
diagnosed at T scores <1 and >2.5 and Z scores <1 and
>2. If scores for both, hip and spine were available, the lowest
scores were considered. For our diagnostic procedure the
following hierarchy was used: if available, the T score was used.
If no T score was available Z score was used. Without
information of DXA scores the diagnosis of osteoporosis/
osteopenia in the patient chart was considered. For 6 patients
an unambiguous reference to a DXA scan was found but no score
and no interpretation was available; these patients were only used
for the analysis of screening rates but not for statistics about
diagnosis and treatment. For the calculations of screening rates
evidence for either osteoporosis/osteopenia within the SIBDCS
data base or any documentation regarding a DXA scan within
patient charts (see above) were taken into account.
2.1. Data analysis
For the multivariate analysis the following variables were
considered: IBD subtype (Crohn disease [CD] vs ulcerative
colitis/indeterminate colitis), gender, last body mass index, last
smoking status, steroid use, presence of intestinal stenosis,
perianal disease, prior intestinal surgery, presence of malabsorp-
tion syndrome, presence of extraintestinal disease manifestations,
Table 1
Recommendations regarding osteoporosis screening in IBD patients according to current guidelines.
Criterion BSG 2007[25,33] ECCO, 2010 (CD) 2013 (UC)[28,29] ACG 2009 (CD),[31] 2010 (UC),[30] and AGA 2003[32]
Steroid usage ≥7.5mg/d for ≥6 mo Repeatedly exposed to steroids >3mo exposure (consecutively or recurrent)
>3mo in the presence of
≥2 additional risk factors
∗
Disease characteristics Persistently/continuing/very active disease Persistently/continuing active disease;
long disease duration
Persistently/continuing active disease
Other criteria Patients in high-risk situations such as age >70y,
disease responding poorly to treatment,
poor nutrition (and other features†)
ACG: smoking, low BMI, sedentary lifestyle,
hypogonadism, family history,
nutritional deﬁciencies, age >60y
AGA: low trauma fracture, postmenopausal
female, male aged >50, hypogonadism
ACG=American College of Gastroenterology, AGA=American Gastroenterological Association, BMI=body mass index, BSG=British Society of Gastroenterology, CD=Crohn disease, ECCO=European Crohn
and Colitis Organization, IBD= inﬂammatory bowel disease, UC=ulcerative colitis.
∗
Additional risk factors (BSG): continuing active disease, weight loss >10%, BMI <20kg/m2, and age >70 y.
† Other features: physical inactivity, use of anticonvulsants, prior osteoporotic fracture, female, untreated early menopause (<45 y of age), late menarche (>15 y of age), short fertile period (<30 y), family history
of osteoporotic fracture, smoking, low calcium intake, poor visual acuity, neuromuscular disorders, and alcohol excess.
Schüle et al. Medicine (2017) 96:22 Medicine
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age at last follow-up, childhood diagnosis of IBD, disease
duration, family history of IBD, alcohol consumption more than
once a day, sport at least once a week, last Activity Index, and
study center, similar to a previous study.[22] For the calculation of
the Activity Index, disease activity was normalized to a parameter
ranging from 0 (no activity) to 100 (strongest activity). Thereby,
for CD patients the Crohn disease activity indexwas divided by 5;
for ulcerative colitis/indeterminate colitis patients the modiﬁed
Truelove and Witts severity index was divided by .21.[22]
Univariate and multivariate logistic regression analyses were
used to determine the association of clinical variables with
osteoporosis screening in IBD patients. We ﬁrst performed
univariate regressions with each factor mentioned above. We
then ﬁt together all variables such that the corresponding P-value
in univariate regressions was less than .2. A step-wise approach
was ﬁnally used to select a model with predictors whose P-value
were less than .157.[44] For this analysis the Stata software was
used (StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX: StatCorp LP).
For the statistical analysis of screening and treatment rates and
trends in BMD according to treatments Fisher exact test and a
linear regression analysis, respectively, were performed, using
appropriate modules of GraphPad Prism, version 6.0d. A P value
at or below .05 was prospectively deﬁned as signiﬁcant.
2.2. Ethical considerations
The SIBDCS protocol has been approved as a multicenter study
by the ethics committee of Zurich County (KEK-ZH). Patients
provided written informed consent to data acquisition and
analysis during inclusion into the SIBDCS. Data analysis was
performed according to the declaration of Helsinki.
3. Results
For our analysis, we used a subgroup of SIBDCS, a large
prospective cohort study of well-characterized Swiss IBD patients.
A chart reviewwasperformed in6 centers.Altogether, data for877
IBD patients could be retrieved. These patients represent a mixed
IBD cohort from tertiary and secondary referral centers with
expected epidemiological characteristics regarding age and gender
distribution as well as IBD characteristics (Table 2).
3.1. Prevalence of osteoporosis screening
In 259 of the 877 patients (30%), osteoporosis screening was
performed. Screening rates differed strongly between centers
ranging from 11% to 62% (Fig. 1). For example, in center A, 90
out of 146 patients (62%) have had a DXA scan; in center B, 83
out of 231 (36%) were screened by DXAwhereas in center F only
25 out of 237 patients (11%) have had a DXA scan. Overall,
screening rates for osteoporosis tended to be slightly higher in
tertiary referral centers compared to secondary centers (30.2%
compared to 24.5%, not signiﬁcant). However, pronounced
differences were also observed within the group of tertiary care
centers (Fig. 1, centers A, B, E, F).
In a multivariate analysis considering multiple risk factors[22]
(see Patients and methods), the study center remained a strong
independent and signiﬁcant predictive factor for the performance
of a DXA scan (Table 3). The following clinical variables were
signiﬁcantly associated with performance of a DXA scan:
presence of perianal disease (odds ratio 1.52; conﬁdence interval
[CI]: 1.04–2.2; P= .032) and usage of any steroid at last visit,
including budesonide (odds ratio 2.2; CI: 1.5–3.2; P< .001).
Treatment with budesonide on its own (instead of all steroids)
Table 2
Epidemiological characteristics of our IBD patients in 2014 from 6
Swiss secondary or tertiary health care centers.
Epidemiology, n=877
Diagnosis Crohn disease: 557 (63.5%)
Ulcerative colitis/indeterminate colitis: 320 (36.5%)
Gender Male: 473 (53.9%)
Female: 404 (46.1%)
Age Mean: 43.7 y, range: 17.1–89.0 y
Body mass index Mean: 24.5kg/m2, range 14.6–48.0kg/m2
Current smoker Total: 228 (26%)
Duration of disease Mean: 14.1 y, range: 0.3–56.6 y
Extent of disease (UC only) Proctitis: 140 (43.8%)
Left-sided colitis: 109 (34.1%)
Pancolitis: 45 (14.1%)
Unknown: 26 (8.1%)
Disease location (CD only) L1 (ileal): 114 (20.5%)
L2 (colonic): 94 (16.9%)
L3 (ileo-colonic): 288 (51.7%)
L4 (upper GI): 9 (1.6%)
Unknown: 52 (9.3%)
Past intestinal surgery UC: 17 (5.3%); CD: 250 (44.9%)
Treatment with anti-TNF
drug ever
Inﬂiximab: 435 (49.6%)
Adalimumab: 170 (19.4%)
Certolizumab: 80 (9.1%)
Any anti-TNF: 481 (54.9%)
CD=Crohn disease, IBD= inﬂammatory bowel disease, TNF= tumor necrosis factor, UC=ulcerative
colitis.
***
***
*****
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Figure 1. Screening for osteoporosis in 6 Swiss IBD Cohort Study centers from inclusion into the study until year 2014. (A) Screening rates per center. In a
conservative approach, screening rates were deﬁned as evidence of osteoporosis/osteopenia in the cohort documentation and/or the patient chart. (B) OR for
having a DXA scan in various centers (compare Table 3). Multivariate analysis:
∗∗∗
P< .001,
∗∗
P< .01,
∗
P< .05. DXA=dual-energy x-ray absorptiometry, IBD=
inﬂammatory bowel disease, OR=odds ratio.
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was also signiﬁcantly associated with osteoporosis screening;
however, the association of all steroids including budesonide
with osteoporosis screening was stronger (ie, resulted in better
model characteristics; not shown). Age at diagnosis, disease
duration, gender, and presence of primary sclerosing cholangitis
did not signiﬁcantly inﬂuence the decision to screen in this
multivariate analysis.
These results suggest that clinicians considered clinical
parameters for their decision to order a DXA scan but clinical
practice differed strongly among centers.
3.2. Prevalence of osteoporosis and osteoporosis risk factors
Overall, 169 of 877 patients (19.3%) had documented decreased
BMD. When only the 253 patients with available DXA scans
were considered, osteopenia was found in 57% and osteoporosis
in 20%. Looking at the different centers separately, among
patients with DXA scans rates for reduced BMD ranged from
43% to 82% and for osteoporosis from 9% to 30% (Fig. 2).
Patients aged ≥50 years (103 out of 253) showed higher rates of
osteoporosis compared to younger patients (29.1% vs 12%,
P= .001); however, the rates of osteopenia did not differ (45.6%
in patients ≥50 years vs 45.3% in patients<50 years). In patients
with a disease duration of ≥15 years (141 out of 253), rates of
osteopenia and osteoporosis did not differ signiﬁcantly (osteo-
penia: 49.6% vs 40.2%; osteoporosis: 20.6% vs 16.1%, ns).
Table 4 provides a comparison of patients with osteoporosis,
osteopenia, and normal BMD. Patients with osteoporosis were
elder, more likely to suffer from CD and more likely to be male
compared to patients with osteopenia and normal BMD, while
disease duration and prevalence of primary sclerosing cholangitis
did not differ signiﬁcantly (Table 4). Rates of steroid treatment at
last visit were highest for osteoporosis (79.2%), intermediate for
osteopenia (62.6%), and lowest for normal BMD (42.2%;
P< .001). Rates of budesonide treatment at last visit also differed
according to BMD but this trend failed to reach signiﬁcance.
Interestingly, the percentage of positive DXA scans was not
related to the screening rate (compare Figs. 1 and 2; no signiﬁcant
association in a Spearmen correlation analysis).
Table 3
Multivariate model for having a DXA scan.
Having had a DXA scan (n=865) Odds ratio (95% CI; P)
Diagnosis
Crohn disease 1 (ref)
Ulcerative colitis .72 (.48–1.09; .12)
Age at last measurement, y 1.008 (.996–1.02; .2)
Last body mass index 1.007 (.97–1.05; .7)
Last activity index
∗
1.006 (.99–1.02; .3)
Steroids at last measurement
No 1 (ref)
Yes 2.2 (1.5–3.2; <.001)
Perianal disease (ﬁstula, ﬁssure, and abscess)
No 1 (ref)
Yes 1.5 (1.04–2.2; .032)
Malabsorption syndrome
No 1 (ref)
Yes .92 (.42–2.05; .8)
Center
Center A 21 (12–38; <.001)
Center B 6.1 (3.6–11; <.001)
Center C 3.9 (2.2–7; <.001)
Center D 3.3 (1.4–7.5; .005)
Center E 2.3 (.85–6.3; .1)
Center F 1 (ref)
Epidemiological parameters (compare Materials and methods) and the center information was used to
calculate a multivariate model of factors associated with osteoporosis screening. CI= conﬁdence
interval, DXA=dual-energy x-ray absorptiometry.
∗
For the calculation of the activity index, the last measurement of Crohn disease activity index was
divided by 5 or the last measurement of the modiﬁed Truelove and Witts severity index was divided by
0.21, respectively.
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Figure 2. Fraction of dual-energy x-ray absorptiometry (DXA) scans diagnostic
for osteopenia or osteoporosis in 6 Swiss study centers from inclusion into the
study until year 2014. Percentage of DXA scans diagnostic for osteoporosis or
osteopenia are shown. Rates of positive ﬁndings did not differ signiﬁcantly (Chi-
square test).
Table 4
Risk factors for osteoporosis in 253 patients with known BMD.
Risk factor Osteoporosis (n=48) Osteopenia (n=115) Normal BMD (n=90) Statistical test
Gender: 123 men, 130 women men: n, % 32 (66.7%) 56 (48.7%) 35 (38.9%) P= .008; Chi2 test
Diagnosis: 170 CD vs 123 UC/IC CD: n, % 39 (81.3%) 69 (60%) 62 (68.9%) P= .028; Chi2 test
Age: median (IQR) range 48.4 (40.0–57.2)
21.5–79.9
41.9 (31.6–54.5)
17.1–70.1
40.9 (32.1–52.3)
21.6–78.1
P= .038; Kruskal–Wallis
Disease duration: median (IQR) range 14.0 (8.0–21.6)
1.2–38.5
12.3 (6.7–22.6)
0.8–40.9
13.0 (7.5–19.5)
1.5–43.6
P= .742 Kruskal–Wallis
PSC: (n=6) n (% of PSC patients) 1 (2.1%) 3 (2.6%) 2 (2.2%) P= .973 Chi2 test
Budesonide ever: 107 yes vs 146 no yes: n, % 21 (43.8%) 41 (35.7%) 45 (50%) P= .116 Chi2 test
Any steroid ever: 228 yes vs 25 no yes: n, % 44 (91.7%) 101 (87.8%) 83 (92.2%) P= .534 Chi2 test
Budesonide at last visit: 62 yes vs 191 no yes: n, % 16 (33.3%) 28 (24.3%) 18 (20.0%) P= .222 Chi2 test
Any steroid at last visit: 148 yes vs 105 no yes: n, % 38 (79.2%) 72 (62.6%) 38 (42.2%) P< .001 Chi2 test
P-values for signiﬁcant differences as determined by the indicated test are shown in bold letters. BMD=bond mineral density, CD=Crohn disease, IC= indeterminate colitis, IQR= interquartile range, PSC=
primary sclerosing cholangitis, UC=ulcerative colitis.
Schüle et al. Medicine (2017) 96:22 Medicine
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3.3. Treatment of osteoporosis
Treatment of reduced BMD differed within our cohort. This
analysis was restricted to 253 patients with known BMD.
Overall, 106 of 253 patients (42%) were treated with calcium
supplementation, 140 (55%) with vitamin D, and 14 (6%) with
bisphosphonates at the time of chart review. Treatment differed
according to BMD: 28/51 (55%) of patients with osteoporosis,
67/143 (47%) of patients with osteopenia, and 26/84 (31%) of
patients with normal BMD were treated with calcium (P= .013,
Chi square test for the whole group, compare Fig. 3A). Similar
but nonsigniﬁcant effects on treatment rates for vitamin D were
recorded and 33/51 (65%) of patients with osteoporosis, 84/143
(59%) of patients with osteopenia, and 40/84 (48%) of patients
with normal BMD received vitamin D supplementation
(P= .112). The fraction of patients that did not receive any
osteoporosis treatment at the time of chart review was 27% for
osteoporosis and 36% for osteopenia.
When the complete treatment history of the patient was
considered, rates for patients ever treated with calcium/vitamin D
increased to 92%/90% for patients with osteoporosis, 83%/87%
for patients with osteopenia, and 61%/70% for patients with
normal BMD.
Centers with higher rates of osteoporosis screening also
showed higher rates for osteoporosis treatment. For the 3 centers
with the highest screening rates (center A–F, Fig. 1) treatment
rates followed screening rates with calcium/vitamin Dmedication
in 54%/71% in center A, 39%/54% in center B, and 27%/34%
in center C. The trend remained robust if subgroups of patients
with osteoporosis or osteopenia were considered.
Patients currently treated with steroids tended to receive
calcium and vitamin D supplementation slightly more frequently
than patients without steroids (10/19; 53% for calcium; 11/19;
58% for vitamin D, not signiﬁcant; Fig. 3B). However, a
considerable fraction of patients with normal BMD and no
previous steroids nevertheless received replacement therapy (2/10
for calcium, 4/10 for vitamin D).
Bisphosphonate treatment was most frequently applied to
patients with osteoporosis: 7 out of 51 osteoporosis patients
(14%) received bisphosphonates at the time of the chart review.
In addition, 11 out of 143 patients (8%) with osteopenia but no
patient with normal BMD received bisphosphonate treatment at
this time. For 13 patients bisphosphonate treatment had been
started but discontinued and 15 out of 51 (29%) of patients with
osteoporosis, 19 out of 143 with osteopenia (13%), and 1 out of
84 patients with normal BMD (1%) had ever received
bisphosphonates. The reasons why treatment was discontinued
were not evaluated.
3.4. Multiple DXA scans and improvement of BMD
Among the 259 IBD patients with DXA screening 129 (50%)
received 1 DXA scan; 72 (28%) were tested twice, 26 (10%) 3
times, and 18 (7%) and 14 (5%) 4 or more times, respectively
(Figure S1, http://links.lww.com/MD/B712). Overall, for all
patients with multiple DXA scans we note a slight improvement
over time in T scores for the hip and the spine in a linear
regression analysis (spine: slope: .06/year, CI: .0099–.12, P= .02;
hip: slope: .04/year, CI: .0002–.081, P= .051, not shown).
However, in the subgroup of patients with calcium or vitamin D
supplementation T scores for spine improved signiﬁcantly
(calcium: slope: .1/year, CI: .036–.17, P= .004; vitamin D: slope:
.091/year, CI: .026–.16, P= .007, vitamin D and calcium: slope
.089/year, CI: .028–.15, P= .005; Fig. 4A and B). In contrast, for
patients without calcium and vitaminD supplementation spinal T
scores did not increase signiﬁcantly over time. Similar results
were obtained for T scores of the hip (not shown). No signiﬁcant
improvement in serial DXA scans of 8 patients with bisphos-
phonate treatment was noted, but the low number of patients in
this subgroup limits our conclusions.
Treatment with any tumor necrosis factor inhibitor (Inﬂix-
imab, Adalimumab, or Certolizumab) was not associated with
improvements in T scores for hip or spine in contrast to 2
previous studies.[45,46]
4. Discussion
In our study, we address clinical practice of osteoporosis
screening and treatment. We found widely differing screening
rates among different IBD referral centers. Furthermore,
osteoporosis treatment frequently did not follow recommenda-
tions, most profoundly in centers with low screening rates. Our
data thus indicate low awareness of osteoporosis as an important
medical problem for IBD patients. However, the subset of
patients with calcium or vitamin D medication signiﬁcantly
improved their BMD over the course of treatment, in turn
indicating, that appropriate evaluation for and treatment of
osteopenia/osteoporosis may ultimately translate into clinical
beneﬁt for patients with IBD.
In 253 patients tested with DXA scans, rates of osteopenia and
osteoporosis were 57% and 20%, respectively. These numbers
are well in agreement with previous studies, reporting osteopenia
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and osteoporosis rates of 34% to 78% and 13% to 42%,
respectively.[20,22,47–52] Although the rate of low BMD of a given
cohort will depend on patient and disease characteristics, our
data conﬁrm osteoporosis and osteopenia as prevalent problems
in IBD patients. Our study also conﬁrms the important role of
steroid treatment for osteoporosis in IBD patients (Table 4).
Screening rates for osteoporosis varied remarkably among the
6 study centers, ranging from 11% to 62%. All patients were
treated by gastroenterologists specialized in IBD care, either in
large academic centers or in large private practices. Nevertheless,
the study center remained a strong and signiﬁcant predictor for
osteoporosis screening in univariate and multivariate analyses.
Clinical variables such as steroid usage, disease duration, and
presence of perianal disease were further predicting factors.
Interestingly, even though the rates of DXA scans strongly
differed among centers, the fraction of positive DXA scans (ie,
with a diagnosis of osteoporosis or osteopenia) did not differ
signiﬁcantly (Fig. 2). Our analysis cannot formally distinguish
between over usage and under usage of DXA scans. However,
our data suggest that either the policy of a given center, awareness
of osteoporosis, and/or availability of DXA scans strongly
inﬂuenced clinical management of IBD patients regarding bone
health.
Current guidelines agree that DXA scan should be recom-
mended in individuals with signiﬁcant steroid use longer than 3
or 6 months or recurrent and/or persistently active disease.
However, compliance to most guidelines cannot be formally
tested since no formal threshold for disease duration or
“persistent” or “continuous” disease activity is deﬁned by
European Crohn and Colitis Organization or British Society of
Gastroenterology guidelines.[25,26,28,29,33] Guidelines of AGA
and ACG provide objective criteria[32] but none of these are
speciﬁc to IBD patients. In 1 study, screening criteria mentioned
by AGA and ACG guidelines did not predict low BMD in
subsequent DXA scans.[53]
Steroid usage is mentioned by all guidelines but details of
recommendations differ. However, during our chart review
extracting steroid dosage over time proved to be time consuming
(up to 1 hour per patient) and frequently an area under the curve
could not be reconstructed with conﬁdence. Considering complex
patient histories or treatment in different clinical settings, we
suspect that these limitations are not speciﬁc to our study and any
screening recommendation based on duration or frequency of
past steroid usage will be hard to implement in a rigorous
manner.
Awareness of osteoporosis was directly tested in 1 previous
study demonstrating low familiarity of physicians of AGA with
guidelines regarding osteoporosis screening and treatment in IBD
patients.[54] According to another prospective study, increasing
physician’s awareness of osteoporosis guidelines can in turn
improve screening rates in IBD patients[55]: guidelines of ACG
were sent to members, prompting additional DXA scans as well
as increased familiarity in osteoporosis treatment, potentially
preventing fractures in IBD patients.
Taken together, heterogeneity in clinical practice (as indicated
by our study) might also reﬂect ambiguity and diversity in current
guidelines. Overutilization and under usage of DXA scans will
clearly limit cost-efﬁciency of osteoporosis screening and guide-
lines easily applicable in clinical practice would be desirable.
Treatment rates regarding calcium and vitamin D generally
followed screening rates. A diagnosis of reduced BMD increased
the likelihood of treatment with vitamin D and/or calcium.
However, 27% and 36% of patients with osteoporosis and
osteopenia, respectively, did not receive treatment. Our data thus
reveal partial noncompliance with osteoporosis treatment
guidelines in Switzerland. Although the vast majority of patients
(almost 92%) with a DXA scan diagnostic for osteoporosis had
received vitamin D and calcium in the past, only 55% of patients
received calcium and 65% received vitamin D at the time of our
chart review. Low treatment rates were also described in previous
studies[53,56] (treatment rates for calcium and/or vitamin D of
59%–63.5% in IBD patients with low BMD).
Treatment with calcium and vitamin D is likely beneﬁcial for
IBD patients with low BMD and an increase in T scores in
sequential DXA scans was noted in patients with calcium and
vitamin D treatment. Similar effects were described in a previous
randomized, placebo controlled study with 60 IBD patients.[57]
In our study, only 29% of all patients with osteoporosis were
ever treated with bisphosphonates and for only 14% of patients
this drugwas part of the current treatment regiment, pointing to a
relevant underutilization of this very efﬁcient osteoporosis
medication.[34–36] Treatment with bisphosphonates can reduce
the incidence of spine and hip fractures by 33% to 50% over 3
years in osteoporotic postmenopausal women.[32,35,36] Underuse
of bisphosphonates is unlikely due to ﬁnancial constraints since
these costs will be reimbursed by the universal Swiss public health
insurance system. Besides bisphosphonates other powerful
osteoporosis treatments are available including calcitonin,
estrogens, PTH analogues, and denosumab.[35] However,
prescription of these modern therapies was noted in only 3
out of 169 patients with low BMD.
Strengths of our study include the high level of patient data
available. Furthermore, to the best of our knowledge, our study is
the ﬁrst comparing clinical practice regarding screening and
treatment rates among individual centers. Our study has several
limitations:
(i) The retrospective study design.
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(ii) Our study population was recruited in secondary and
tertiary referral centers and might not be representative for
the Swiss population affected by IBD.
(iii) Our analysis was limited to results of DXA scans and
fractures were not considered.
(iv) We did not analyze biochemical markers for systemic
inﬂammation[21,58] or intestinal inﬂammation such as
calprotectin, bone turnover,[47,50,58] or genetic markers for
osteoporosis[59] as done in some previous studies.
(v) We did not systematically assess comorbidities of our
patients besides IBD; however, only 10.7% of all patients
and 11% of patients with DXA scans were older than 65
years and the inﬂuence of comorbidities might be limited.
5. Conclusion
Our analysis identiﬁed inconsistent usage of osteoporosis
screening and underuse of osteoporosis treatment with calcium,
vitamin D, and bisphosphonates in IBD patients. Screening and
treatment rates strongly differed among centers and opportu-
nities for improving treatment remain inmany centers. Treatment
with calcium and vitamin D improved BMD inDXA scans. Better
physician awareness regarding osteoporosis might thus improve
bone health of IBD patients.
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